BR112017028639A2 - composto novo que se liga especificamente ao receptor ampa, composição farmacêutica e método para a produção do mesmo - Google Patents

composto novo que se liga especificamente ao receptor ampa, composição farmacêutica e método para a produção do mesmo

Info

Publication number
BR112017028639A2
BR112017028639A2 BR112017028639-4A BR112017028639A BR112017028639A2 BR 112017028639 A2 BR112017028639 A2 BR 112017028639A2 BR 112017028639 A BR112017028639 A BR 112017028639A BR 112017028639 A2 BR112017028639 A2 BR 112017028639A2
Authority
BR
Brazil
Prior art keywords
ampa receptor
producing
pharmaceutical composition
specifically binds
new compound
Prior art date
Application number
BR112017028639-4A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017028639B1 (pt
Inventor
Takahashi Takuya
Miyazaki Tomoyuki
Suhara Tetsuya
Higuchi Makoto
Cho Meiei
Original Assignee
Public University Corporation Yokohama City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Public University Corporation Yokohama City University filed Critical Public University Corporation Yokohama City University
Publication of BR112017028639A2 publication Critical patent/BR112017028639A2/pt
Publication of BR112017028639B1 publication Critical patent/BR112017028639B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

a presente invenção fornece um composto representado pela fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um solvato do mesmo. [comp 1] (na fórmula, cada um de a e z representa independentemente co, so ou so2; cada um de x e y representa independentemente s ou o; cada um de r1-r4 representa independentemente hidrogênio, alquila, alquenila, alquinila ou halo; cada r5 representa independentemente alquila, alquenila, alquinila ou halo; e n representa um número inteiro de 0-4.) este composto é capaz de se ligar especificamente a um receptor de ampa e mostra absorção cerebral extremamente alta.
BR112017028639-4A 2015-07-06 2016-07-05 Composto que liga especificamente ao receptor ampa, composição farmacêutica que o compreende, uso do mesmo e métodos para a produção do referido composto e para a formação de imagem de um receptor ampa BR112017028639B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-135124 2015-07-06
JP2015135124 2015-07-06
PCT/JP2016/069896 WO2017006931A1 (ja) 2015-07-06 2016-07-05 Ａｍｐａ受容体に特異的に結合する新規化合物

Publications (2)

Publication Number Publication Date
BR112017028639A2 true BR112017028639A2 (pt) 2018-09-11
BR112017028639B1 BR112017028639B1 (pt) 2023-03-21

Family

ID=57685631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028639-4A BR112017028639B1 (pt) 2015-07-06 2016-07-05 Composto que liga especificamente ao receptor ampa, composição farmacêutica que o compreende, uso do mesmo e métodos para a produção do referido composto e para a formação de imagem de um receptor ampa

Country Status (18)

Country Link
US (1) US10335503B2 (pt)
EP (1) EP3321252B1 (pt)
JP (1) JP6425817B2 (pt)
KR (1) KR101997699B1 (pt)
CN (1) CN107922328B (pt)
AU (1) AU2016289031C1 (pt)
BR (1) BR112017028639B1 (pt)
CA (1) CA2991400C (pt)
DK (1) DK3321252T3 (pt)
ES (1) ES2829638T3 (pt)
HK (1) HK1250230A1 (pt)
IL (1) IL256735B (pt)
MX (1) MX2018000242A (pt)
PL (1) PL3321252T3 (pt)
RU (1) RU2705595C2 (pt)
SG (1) SG11201800071PA (pt)
TW (1) TWI675820B (pt)
WO (1) WO2017006931A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6241974B1 (ja) * 2017-01-11 2017-12-06 公立大学法人横浜市立大学 霊長類生体の脳内ａｍｐａ受容体のイメージング方法、プログラム、及びスクリーニング方法
JP2020045285A (ja) * 2017-01-11 2020-03-26 公立大学法人横浜市立大学 Ａｍｐａ受容体に関連する疾患の予防及び／又は治療剤
US11439715B2 (en) 2017-08-28 2022-09-13 Neurovation Labs, Inc. Compositions and methods to detect GLUA1 in brain and to identify the presence of GLUA1-mediated post-traumatic stress disorder and other neurological disorders
CN110483343B (zh) * 2019-09-03 2021-08-27 泰州职业技术学院 一种新型的磺酰氯衍生物、其制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189211A (en) * 1990-08-01 1993-02-23 Taisho Pharmaceutical Co., Ltd. Sulfonamide derivatives
KR19980702372A (ko) * 1995-02-21 1998-07-15 구니이 야쓰오 글루타민산 수용체 작용약
UA67749C2 (uk) * 1997-08-12 2004-07-15 Егіш Дьйодьсердьяр Рт. Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування
BRPI0111596B8 (pt) 2000-06-12 2022-07-26 Eisai Co Ltd Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2011002884A (es) * 2008-09-17 2011-04-21 Suven Life Sciences Ltd Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
JP5455396B2 (ja) 2009-02-27 2014-03-26 知之 西崎 プロテインホスファターゼ−１阻害剤
WO2011002096A1 (ja) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Ｐｅｔ用標識化合物
JP2016522786A (ja) * 2013-04-04 2016-08-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ［１１ｃ］及び［１８ｆ］標識化１，３−ジフェニルー５−（ピリミジン−２−イル）−ピリジン−２（１ｈ）−オン誘導体並びにａｍｐａ受容体のｐｅｔイメージングのためのそれらの使用
WO2015066456A1 (en) * 2013-10-31 2015-05-07 Bristol-Myers Squibb Company Radioligands for imaging the lpa-1 receptor

Also Published As

Publication number Publication date
IL256735A (en) 2018-03-29
EP3321252A1 (en) 2018-05-16
TWI675820B (zh) 2019-11-01
TW201706242A (zh) 2017-02-16
CA2991400C (en) 2020-05-12
US20180200391A1 (en) 2018-07-19
PL3321252T3 (pl) 2021-04-06
RU2705595C2 (ru) 2019-11-11
SG11201800071PA (en) 2018-02-27
MX2018000242A (es) 2018-03-08
EP3321252B1 (en) 2020-10-21
AU2016289031B2 (en) 2019-07-18
JP6425817B2 (ja) 2018-11-21
HK1250230A1 (zh) 2018-12-07
ES2829638T3 (es) 2021-06-01
IL256735B (en) 2021-02-28
KR20180025951A (ko) 2018-03-09
WO2017006931A1 (ja) 2017-01-12
JPWO2017006931A1 (ja) 2018-06-21
BR112017028639B1 (pt) 2023-03-21
US10335503B2 (en) 2019-07-02
KR101997699B1 (ko) 2019-07-08
RU2018104555A3 (pt) 2019-08-06
CN107922328B (zh) 2020-05-19
DK3321252T3 (da) 2020-11-16
CA2991400A1 (en) 2017-01-12
RU2018104555A (ru) 2019-08-06
CN107922328A (zh) 2018-04-17
EP3321252A4 (en) 2019-03-13
AU2016289031C1 (en) 2019-10-17
AU2016289031A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
BR112017028639A2 (pt) composto novo que se liga especificamente ao receptor ampa, composição farmacêutica e método para a produção do mesmo
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
BR112018016490A2 (pt) derivados de 6,7-di-hidro-5h-benzo[7]anuleno como moduladores de receptor de estrogênio
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112018005194A2 (pt) processo de composto antifúngico
CO2020006224A2 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BR112018067995A2 (pt) composição oftalmológica
BR112017000242A2 (pt) composto, cristal, inibidor de axl, medicamento, composição farmacêutica, métodos para tratamento de uma doença, para prevenção de metástases de câncer, para superar a resistência a drogas de um câncer e para inibir a aquisição de resistência a drogas de um câncer, e, uso de um composto
BR112017006430A2 (pt) composto pirimidinona
BR112018010564A2 (pt) composições farmacêuticas compreendendo levodopa amida e usos das mesmas
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
BR112015021443A2 (pt) novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
PH12019500822A1 (en) Crystalline forms of eravacycline
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112018015851A2 (pt) composto, e, medicamento.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/07/2016, OBSERVADAS AS CONDICOES LEGAIS